Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Current Leases (2021 - 2025)

Historic Current Leases for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $1.7 million.

  • Krystal Biotech's Current Leases rose 3142.41% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 3142.41%. This contributed to the annual value of $1.2 million for FY2024, which is 1743.55% down from last year.
  • As of Q3 2025, Krystal Biotech's Current Leases stood at $1.7 million, which was up 3142.41% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Current Leases peaked at $1.7 million during Q3 2025, and registered a low of $648000.0 during Q1 2021.
  • For the 5-year period, Krystal Biotech's Current Leases averaged around $1.3 million, with its median value being $1.4 million (2022).
  • Per our database at Business Quant, Krystal Biotech's Current Leases surged by 11774.69% in 2022 and then tumbled by 1743.55% in 2024.
  • Krystal Biotech's Current Leases (Quarter) stood at $1.0 million in 2021, then skyrocketed by 49.95% to $1.6 million in 2022, then dropped by 5.57% to $1.5 million in 2023, then dropped by 17.44% to $1.2 million in 2024, then surged by 39.52% to $1.7 million in 2025.
  • Its Current Leases was $1.7 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.4 million in Q1 2025.